Dermata Therapeutics (Dermata Therapeutics) ROCE % : -252.21% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dermata Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -252.21%.

Dermata Therapeutics ROCE % Historical Data

The historical data trend for Dermata Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics ROCE % Chart

Dermata Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-1,303.50

-226.79

-119.97

-129.96

Dermata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial													-129.17	-85.97	-100.42	-139.17	-252.21

Dermata Therapeutics ROCE % Calculation

Dermata Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.042	/	( ( (6.944 - 0.923)	+	(7.979 - 1.624) )	/ 2 )
	=	-8.042	/	( (6.021	+	6.355)	/ 2 )
	=	-8.042	/	6.188
	=	-129.96 %

Dermata Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-12.816	/	( ( (7.979 - 1.624)	+	(5.18 - 1.372) )	/ 2 )
	=	-12.816	/	( ( 6.355	+	3.808 )	/ 2 )
	=	-12.816	/	5.0815
	=	-252.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Dermata Therapeutics (NAS:DRMAW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dermata Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMAW) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DRMA:USA

Address

3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130

Website

https://www.dermatarx.com

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.